Chairperson: Beth Lambert (Herbalist & Alchemist)
Staff Contact: Natasha Weaver
AHPA Members, if you would like to join this committee, please email the staff contact.
Webinar presenters explain ways to ensure your marketing claims for herbal immune support products are substantiated, truthful and not misleading. Industry experts review several methods they’ve used to ensure their dietary supplement product claims are well substantiated, including: randomized, controlled clinical trials on a well-known elderberry product; in vitro testing to support the legitimacy of the product; and the relevance of use and training in substantiating the effectiveness of traditional Chinese herbal formulations.
This webinar provides an overview of dietary supplement current good manufacturing (cGMP) requirements for hemp-CBD products. Legal and industry experts provide strategies and resources to comply and document compliance with federal manufacturing requirements designed to ensure supplement product quality and safety.
Recorded October 29, 2019, this webinar offers expert insights into the nutrition labeling requirements for foods and dietary supplements are scheduled to take effect January 1, 2020 for manufacturers with $10 million or more in annual sales and January 1, 2021 for smaller manufacturers.
Effective January 3, 2020, the Office of Environmental Health Hazard Assessment added cannabis (marijuana) smoke and Δ9-tetrahydrocannabinol (Δ9-THC) to the list of chemicals known to the state to cause reproductive toxicity (developmental endpoint) for purposes of California Proposition 65 (Prop 65). At a public meeting on December 11, 2019, the Developmental and Reproductive Toxicant Identification Committee (DARTIC) in its official capacity as the “state’s qualified experts” determined that cannabis (marijuana) smoke and Δ9-tetrahydrocannabinol (Δ9-THC) were shown to cause reproductive toxicity based on the developmental endpoint.
Attend this webinar to learn how to successfully traverse the NDI notification process and avoid common pitfalls that can result in FDA objections.
Recorded September 20, 2018 -- Duration: 2 hours
2021 Annual Fund Sponsors
AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.